Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study

被引：0

作者：

Platzbecker, U. ^{[1
]}

Della Porta, M. G. ^{[2
,3
]}

Santini, V. ^{[4
]}

Zeidan, A. M. ^{[5
,6
]}

Fenaux, P. ^{[7
]}

Komrokji, R. S. ^{[8
]}

Shortt, J. ^{[9
,10
]}

Valcarcel, D. ^{[11
]}

Jonasova, A. ^{[12
]}

Dimicoli-Salazar, S. ^{[13
]}

Tiong, I. S. ^{[14
]}

Lin, C. -C. ^{[15
]}

Li, J. ^{[16
]}

Zhang, J. ^{[16
]}

Giuseppi, A. C. ^{[16
]}

Kreitz, S. ^{[17
]}

Pozharskaya, V. ^{[16
]}

Keeperman, K. L. ^{[16
]}

Rose, S. ^{[16
]}

Shetty, J. K. ^{[17
]}

Hayati, S. ^{[16
]}

Vodala, S. ^{[16
]}

Degulys, A. ^{[18
,19
]}

Paolini, S. ^{[20
]}

Cluzeau, T. ^{[21
]}

Garcia-Manero, G. ^{[22
]}

机构：

[1] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[2] IRCCS Humanitas Res Hosp, Ctr Canc, Milan, Italy

[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[4] Univ Florence, MDS Unit, AOUC, Hematol, Florence, Italy

[5] Yale Univ, Yale Sch Med, New Haven, CT USA

[6] Yale Canc Ctr, Dept Internal Med, New Haven, CT USA

[7] Univ Paris 07, Serv Hematol Seniors, Hop St Louis, Paris, France

[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[9] Monash Univ, Melbourne, Vic, Australia

[10] Monash Hlth, Melbourne, Vic, Australia

[11] Hosp Univ Vall dHebron, Barcelona, Spain

[12] Charles Univ Prague, Gen Univ Hosp, Dept Med Hematol, Prague, Czech Republic

[13] Hop Haut Leveque, Ctr Hosp Univ Bordeaux, Bordeaux, France

[14] The Alfred, Malignant Haematol & Stem Cell Transplantat, Melbourne, Vic, Australia

[15] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Celgene Int Sarl, Boudry, Switzerland

[18] Vilnius Univ Hosp Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania

[19] Vilnius Univ, Inst Clin Med, Fac Med, Vilnius, Lithuania

[20] IRCCS Univ Hosp Bologna, Seragnoli Inst Hematol, Bologna, Italy

[21] Univ Cote dAzur, CHU Nice, Dept Hematol Clin, Nice, France

[22] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V61

引用

页码：16 / 17

页数：2

共 35 条

[31] Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Platzbecker, Uwe
Fenaux, Pierre
Steensma, David P.
Van Eygen, Koen
Raza, Azra
Germing, Ulrich
Font, Patricia
Diez-Campelo, Maria
Thepot, Sylvain
Vellenga, Edo
Patnaik, Mrinal M.
Jang, Jun Ho
Sherman, Laurie
Dougherty, Souria
Sun, Libo
Huang, Fei
Wan, Ying
Rizo, Aleksandra
Berry, Tymara
Feller, Faye
Santini, Valeria
BLOOD, 2020, 136
[32] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Santini, Valeria
Almeida, Antonio
Giagounidis, Aristoteles
Groepper, Stefanie
Jonasova, Anna
Vey, Norbert
Mufti, Ghulam J.
Buckstein, Rena
Mittelman, Moshe
Platzbecker, Uwe
Shpilberg, Ofer
Ram, Ron
del Canizo, Consuelo
Gattermann, Norbert
Ozawa, Keiya
Risueno, Alberto
MacBeth, Kyle J.
Zhong, Jianhua
Seguy, Francis
Hoenekopp, Albert
Beach, C. L.
Fenaux, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
[33] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
Santini, V.
Almeida, A.
Giagounidis, A.
Groepper, S.
Jonasova, A.
Vey, N.
Mufti, G. J.
Buckstein, R.
Mittelman, M.
Platzbecker, U.
Shpilberg, O.
Ram, R.
del Canizo, C.
Gattermann, N.
Ozawa, K.
Risueno, A.
MacBeth, K. J.
Zhong, J.
Seguy, F.
Hoenekopp, A.
Beach, C. L.
Fenaux, P.
LEUKEMIA RESEARCH, 2015, 39 : S60 - S61
[34] Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
Santini, Valeria
Almeida, Antonio
Giagounidis, Aristoteles
Groepper, Stephanie
Jonasova, Anna
Vey, Norbert
Mufti, Ghulam J.
Buckstein, Rena
Mittelman, Moshe
Platzbecker, Uwe
Shpilberg, Ofer
Ram, Ron
del Canizo, Consuelo
Gattermann, Norbert
Ozawa, Keiya
Zhong, Jim
Seguy, Francis
Hoenekopp, Albert
Beach, C. L.
Fenaux, Pierre
BLOOD, 2014, 124 (21)
[35] Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Garcia-Manero, Guillermo
Mufti, Ghulam J.
Fenaux, Pierre
Buckstein, Rena
Santini, Valeria
Diez-Campelo, Maria
Finelli, Carlo
Cazzola, Mario
Ilhan, Osman
Sekeres, Mikkael A.
List, Alan F.
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Rampersad, Anita
Sinsimer, Daniel
Linde, Peter G.
Platzbecker, Uwe
Komrokji, Rami
BLOOD, 2019, 134

← 1 2 3 4 →